Literature DB >> 15150646

[Health care costs of multiple sclerosis in Austria. Cross-sectional study including consideration of quality of life].

U Ganzinger1, C Badelt, K Vass, S Strasser-Fuchs, F Fazekas, T Berger, F Dahlke.   

Abstract

A retrospective, cross-sectional study was performed to evaluate direct and indirect costs related to multiple sclerosis (MS) in Austria in a representative cohort of patients ( n=895) with typical symptoms. Demographic, socioeconomic, and disease-related data including degree of disability and health-related quality of life as well as consumption of medical and nonmedical resources were recorded and mean total costs per patient and year were calculated (based on 1999 figures). Total direct costs borne by public sources were 15,684 euro per MS patient per year. Overall societal costs increased disproportionately with the progression of the disease, from 12,990 euro per year in patients with mild disability to 69,554 euro per year in patients with severe disability. Increasing disability was reflected by substantial deterioration of health status-related quality of life. Direct costs of MS in Austria are similar to those in other countries.

Entities:  

Mesh:

Year:  2004        PMID: 15150646     DOI: 10.1007/s00115-004-1732-5

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  8 in total

Review 1.  Interferons in relapsing remitting multiple sclerosis: a systematic review.

Authors:  Graziella Filippini; Luca Munari; Barbara Incorvaia; George C Ebers; Chris Polman; Roberto D'Amico; George P A Rice
Journal:  Lancet       Date:  2003-02-15       Impact factor: 79.321

Review 2.  Quality of life and cost of multiple sclerosis.

Authors:  Carolin Miltenburger; Gisela Kobelt
Journal:  Clin Neurol Neurosurg       Date:  2002-07       Impact factor: 1.876

Review 3.  The economics of multiple sclerosis. Distribution of costs and relationship to disease severity.

Authors:  A N Grudzinski; Z Hakim; E R Cox; J L Bootman
Journal:  Pharmacoeconomics       Date:  1999-03       Impact factor: 4.981

4.  The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy.

Authors:  Maria Pia Amato; Mario A Battaglia; Domenico Caputo; Giovanni Fattore; Simone Gerzeli; Michele Pitaro; Arturo Reggio; Maria Trojano
Journal:  J Neurol       Date:  2002-02       Impact factor: 4.849

5.  [Multiple sclerosis: cost of the illness].

Authors:  E Tissot; M C Woronoff-Lemsi
Journal:  Rev Neurol (Paris)       Date:  2001-09       Impact factor: 2.607

6.  Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden.

Authors:  F Henriksson; S Fredrikson; T Masterman; B Jönsson
Journal:  Eur J Neurol       Date:  2001-01       Impact factor: 6.089

7.  Prevalence of multiple sclerosis in Austria. Results of a nationwide survey.

Authors:  U Baumhackl; G Eibl; U Ganzinger; H P Hartung; B Mamoli; K P Pfeiffer; F Fazekas; K Vass
Journal:  Neuroepidemiology       Date:  2002 Sep-Oct       Impact factor: 3.282

8.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

  8 in total
  1 in total

1.  EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review.

Authors:  Valentina Prevolnik Rupel; Marko Divjak; Zsombor Zrubka; Fanni Rencz; László Gulácsi; Dominik Golicki; Dagmara Mirowska-Guzel; Judit Simon; Valentin Brodszky; Petra Baji; Jakub Závada; Guenka Petrova; Alexandru Rotar; Márta Péntek
Journal:  Eur J Health Econ       Date:  2019-05-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.